

Table S1. Characteristics of adenocarcinoma cohorts with EGFR/KRAS mutation status and NSCLC cohorts used for treatment prediction used in the current study.

Adenocarcinoma cohorts with known <i>EGFR/KRAS</i> mutation status			
	EGFR-mutated	KRAS-mutated	EGFRwt/KRASwt
Fouret et al. (E-MTAB-923, Affymetrix U133 2plus) (n=103)	49	17	33
Female	41	15	28
Male	8	2	5
Stage I	27	8	22
Stage II	3	2	5
Stage III	19	7	6
Never-smoker	42	2	15
Smoker	7	15	18
Okayama et al. (GSE31210, Affymetrix U133 2plus) (n=226)	127	20	79
Female	77	8	36
Male	50	12	43
Stage I	103	14	51
Stage II	24	6	28
Never-smoker	67	10	38
Smoker	60	10	41
Chitale et al. (Affymetrix U133A) (n=91)	15	11	65
Female	11	8	31
Male	4	3	34
Stage I	9	7	37
Stage II	4	2	14
Stage III	2	2	14
Never-smoker	6	1	10
Smoker	9	9	55
Chitale et al. (Affymetrix U133 2plus) (n=102)	24	36	42
Female	19	20	21
Male	5	16	21
Stage I	18	21	31
Stage II	1	3	6
Stage III	5	8	4
Stage IV	0	4	1
Never-smoker	14	3	2
Smoker	10	33	40
Tomida et al. (GSE13213, Agilent 4x44K) (n=117)	45	15	57
Female	32	2	23
Male	13	13	34
Stage I	29	10	40
Stage II	6	0	7
Stage III	10	5	10
Never-smoker	30	3	23
Smoker	15	12	34

NSCLC cohorts used for treatment prediction analysis			
Byers et al. (GSE33072, Affymetrix 1.0 ST, Sorafenib-treated, n=30)	AC* (n=17)	NSCLC (n=8)	Squamous cell carcinoma (n=5)
Sorafenib-treated	17	8	5
EGFRwt/KRASwt	17	8	5
Female	9	4	1
Male	8	4	4
Stage I	0	0	1
Stage II	1	0	1
Stage III	4	1	1
Stage IV	12	7	2
Never-smoker	4	2	0
Smoker	13	6	5
Tang et al. (GSE42127, Illumina WG6 v3, n=176)	Adenocarcinoma (n=133)		Squamous cell carcinoma (n=43)
No adjuvant chemotherapy	94		33
Adjuvant chemotherapy	39		10
Female	65		18
Male	68		25
Stage I	89		23
Stage II	22		10
Stage III	20		10
Stage IV	1		0
Zhu et al. (GSE14814, Affymetrix U133A, n=90)	AC* (n=28)	Other (n=10)	Squamous cell carcinoma (n=52)
No adjuvant chemotherapy	11	4	25
Adjuvant chemotherapy	17	6	27
Female	15	2	6
Male	13	8	46
Stage I	14	6	25
Stage II	14	4	27

* AC: Adenocarcinoma